Table 3.
Magnitude of Effect for Significant Factors Associated with HRQOL (p<0.05) from Multivariate Model
| Age (decade) | Asian | Side effects | Country (US ref) | Complications | Female | Transfused | |
|---|---|---|---|---|---|---|---|
| Physical Functioning | −2.28 | −2.64 | Canada −1.69 UK −9.42 |
−2.63 | |||
| Role-Physical | −1.93 | −1.63 |
Canada −2.14
UK −9.45 |
||||
| Bodily Pain | −2.97 | Canada 0.79 UK −8.96 |
−1.16 | ||||
| General Health | −2.22 | −1.62 | −1.17 | 5.46 | |||
| Vitality | −1.57 | −3.29 | −2.37 | Canada 0.87 UK −6.86 |
−0.98 | ||
| Social Functioning | −2.25 | −2.37 | Canada −1.99 UK −6.58 |
||||
| Role-Emotional | −1.92 |
Canada −2.05
UK −10.20 |
−3.13 | ||||
| Mental Health | −1.67 | Canada 0.59 UK −4.83 |
−1.10 | ||||
| Physical Summary | −2.12 | −1.80 | Canada −0.09 UK −8.03 |
−0.87 | |||
| Mental Summary | −1.79 | Canada −0.41 UK −5.91 |
Highlighted effects (greater than 2 points) may be considered clinically relevant